47 completed, 37 recruiting, 20 active not recruiting, 13 unknown. 60 Phase 2, 37 Phase 1, 14 Not applicable, 4 Phase 3, 2 Early Phase 1.
Follow Myeloproliferative Neoplasm: new trials by email Literature Review of Myeloproliferative Neoplasm trials Research Report on Myeloproliferative Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Pragmatic Clinical Trial to Prevent Relapse for Myeloid Malignancies With Measurable Disease Prior to Allogeneic Transplant Maintenance Therapy, No intervention - Myeloid Disorders, Myelodysplastic Syndromes | Phase 2 | Not yet recruiting | Medical College of Wisconsin | 450 | 2026-12-01 | 2026-10-13 |
| Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast Phase Myeloproliferative Neoplasms Pacritinib, Venetoclax, Azacitidine - Myeloproliferative Neoplasm | Phase 1 | Not yet recruiting | Roswell Park Cancer Institute | 20 | 2026-12-01 | 2026-10-21 |
| Automated Total Marrow and Lymphoid Irradiation for Allogeneic Hematopoietic Cell Transplant VMAT-Based Total Marrow and Lymphoid Irradiation (TMLI), Fludarabine, Cyclophosphamide - Acute Myeloid Leukemia, Myeloproliferative Neoplasm | Phase 2 | Not yet recruiting | Stanford University | 30 | 2026-11-01 | 2026-09-30 |
| Replacing Bone Marrow Diagnostics With Peripheral Blood Analysis in MPN Patients PERIBLOOD-MPN - Myeloproliferative Neoplasm | Not yet recruiting | Weizmann Institute of Science | 500 | 2026-10-01 | 2026-09-01 | |
| Pulmonary Hypertension and RV Dysfunction in Myeloproliferative Neoplasms Myeloproliferative Neoplasm, Right Ventricular Dysfunction | Not yet recruiting | Assiut University | 145 | 2026-09-20 | 2026-09-22 | |
| A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant Biospecimen Collection, Electronic Health Record Review, Haploidentical Hematopoietic Cell Transplantation - Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | City of Hope Medical Center | 46 | 2026-09-09 | 2026-10-23 |
| Pacritinib With Aza for Upfront Myelodysplastic Syndrome Pacritinib, Azacitidine, Bone Marrow Biopsy and Aspirate - Myelodysplastic Syndromes, MDS | Phase 1 / Phase 2 | Withdrawn | Thomas Jefferson University | 2026-09-01 | 2026-08-17 | |
| Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Polycythemia Vera Ropeginterferon alfa-2b, Phlebotomy and aspirin - Polycythemia Vera, Myeloproliferative Neoplasm | Phase 4 | Withdrawn | PharmaEssentia | 2026-08-01 | 2026-07-31 | |
| Caris Chromoseq Data Collection Caris Chromoseq - Acute Myeloid Leukemia (AML), Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases | Recruiting | Caris Science, Inc. | 300 | 2026-07-01 | 2026-07-02 | |
| Prognostic Value of NETosis Markers for Thrombosis During Myeloproliferative Neoplasms (AVATARE) Additional blood sampling - Myeloproliferative Neoplasm, Myeloproliferative Disorders | Not applicable | Recruiting | University Hospital, Bordeaux | 300 | 2025-12-09 | 2026-01-13 |
| P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk Ropeginterferon alfa-2b, Placebo - Primary Myelofibrosis, Myeloproliferative Neoplasm | Phase 3 | Active not recruiting | PharmaEssentia | 160 | 2025-07-18 | 2026-08-13 |
| Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Biopsy - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 | Recruiting | City of Hope Medical Center | 35 | 2025-04-18 | 2026-06-29 |
| Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care LLS Program - Leukemia, Lymphoma | Not applicable | Recruiting | University of Miami | 400 | 2025-02-04 | 2026-10-16 |
| Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms ASTX029, ASTX727 - Pathway Mutant Myelodysplastic Syndromes, Myelodysplastic Neoplasm | Phase 1 / Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2025-01-31 | 2026-02-13 | |
| Evaluation of the Pathobiology of CALR-mutated MPN Cells Blood Draw - Myeloproliferative Neoplasm | Recruiting | Wake Forest University Health Sciences | 35 | 2025-01-21 | 2026-07-13 | |
| Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT Cellular therapy product - Allogeneic Stem Cell Transplant Candidate, Acute Myeloid/Lymphoblastic Leukemia | Phase 1 | Withdrawn | Leland Metheny | 2024-12-01 | 2024-12-05 | |
| Prevalence and Risk Factors of Pulmonary Hypertension in Patients with Myeloproliferative Neoplasms in Assiut University Hospital. Transthoracic echocardiography - Myeloproliferative Neoplasm | Not yet recruiting | Assiut University | 100 | 2024-11-01 | 2024-10-18 | |
| Brain MRF in Children, Adolescents and Young Adults With Acute Leukemia MRF with neurocognative studies - Acute Leukemia, Acute Lymphoblastic Leukemia, Pediatric | Not applicable | Recruiting | Case Comprehensive Cancer Center | 20 | 2024-10-04 | 2026-10-20 |
| Evaluation of the Prognostic Impact of Decreased Serum beta2 Microglobulin in the First Year of Follow-up of Myeloproliferative Neoplasia (PRODIGE) Myeloproliferative Neoplasm | Unknown | University Hospital, Brest | 50 | 2024-08-12 | 2024-08-14 | |
| Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases Biospecimen Collection, Bone Marrow Aspirate, Cyclophosphamide - Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 54 | 2024-07-23 | 2026-10-26 |
Showing 20 of 144. Sign in to see all of them.
Myeloproliferative Disorders (144) · Myelodysplastic Syndromes (74) · Leukemia, Myeloid, Acute (60) · Primary Myelofibrosis (34) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (32) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (26) · Hodgkin Disease (24) · Leukemia, Lymphocytic, Chronic, B-Cell (23) · Lymphoma, Non-Hodgkin (21) · Leukemia, Myelomonocytic, Chronic (20) · Multiple Myeloma (16) · Polycythemia Vera (14) · Thrombocythemia, Essential (14) · Hematologic Neoplasms (13) · Leukemia (12)
Hemic and Lymphatic Diseases (144) · Bone Marrow Diseases (142) · Hematologic Diseases (142) · Neoplasms (89) · Neoplasms by Histologic Type (85) · Leukemia, Myeloid (71) · Leukemia (70) · Pathologic Processes (58) · Pathological Conditions, Signs and Symptoms (58) · Disease Attributes (55) · Chronic Disease (53) · Immune System Diseases (49) · Immunoproliferative Disorders (48) · Lymphatic Diseases (48) · Lymphoproliferative Disorders (46)
Cyclophosphamide (19) · Whole-Body Irradiation (16) · Mycophenolic Acid (13) · Peripheral Blood Stem Cell Transplantation (13) · Tacrolimus (13) · fludarabine phosphate (13) · Azacitidine (12) · fludarabine (12) · Cytarabine (9) · venetoclax (8) · Busulfan (7) · Cyclosporine (7) · Cyclosporins (7) · Specimen Handling (7) · Blood Specimen Collection (6)
M.D. Anderson Cancer Center (11) · City of Hope Medical Center (10) · Fred Hutchinson Cancer Center (9) · H. Lee Moffitt Cancer Center and Research Institute (5) · University Hospital, Bordeaux (5) · University Hospital, Brest (5) · Case Comprehensive Cancer Center (4) · National Cancer Institute (NCI) (4) · St. Petersburg State Pavlov Medical University (4) · University Hospital, Angers (4) · Assiut University (3) · Roswell Park Cancer Institute (3) · University of Washington (3) · AbbVie (2) · Children's Oncology Group (2)
United States (93) · France (22) · Canada (8) · Italy (8) · China (6) · Spain (6) · United Kingdom (6) · Germany (5) · Russia (4) · Japan (3) · Puerto Rico (3) · Taiwan (3) · Australia (2) · Bulgaria (2) · Croatia (2)
Ryotaro Nakamura, MD (3) · Anna Halpern (2) · Brenda Sandmaier (2) · Courtney DiNardo, MD (2) · Fang Liu, MD, PhD (2) · Hongyu Zhang, MD, PhD (2) · Marie Bleakley (2) · Maro Ohanian (2) · Monzr M Al Malki (2) · Ryotaro Nakamura (2) · Aaron Gerds, MD (1) · Aleksander Chojecki, MD (1)
PMID 28543980, PMID 32499241, PMID 10204198, PMID 15793561, PMID 24325356, PMID 25027569, PMID 26486786, PMID 27410923, PMID 27760761, PMID 30409796, PMID 30630975, PMID 31033443, PMID 31248843, PMID 32014125, PMID 32040960, PMID 32478814, PMID 33049057, PMID 33075130, PMID 33449813, PMID 33600210, PMID 33720354, PMID 34156440, PMID 34407546, PMID 34507355, PMID 34889407, PMID 35007321, PMID 35349491, PMID 36053823, PMID 36936918, PMID 37339483, PMID 37352262, PMID 37422688, PMID 38423051, PMID 38744144, PMID 38775157, PMID 40073835, PMID 40513054, PMID 40844514, PMID 41124669, PMID 41592279, PMID 41671533
P30CA015704 (8), P30CA033572 (5), P01CA018029 (4), P30CA016672 (2), 2023 (1), P01CA049605 (1), P30CA006516 (1), P30CA006973 (1), P30CA012197 (1), P30CA072720 (1), R01CA061508 (1), R01CA077544 (1), R01CA181045 (1), R01CA183559 (1), R01CA266783 (1)